Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia

Haematologica

Volumn 93, Issue 8, 2008, Pages 1247-1251

  Harmatz, Paul ^a   Jonas, Maureen M ^b   Kwiatkowski, Janet L ^c   Wright, Elizabeth C ^d   Fischer, Roland ^a,h   Vichinsky, Elliott ^a   Giardina, Patricia J ^e   Neufeld, Ellis J ^b   Porter, John ^f   Olivieri, Nancy ^g  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d NEW ENGLAND RESEARCH INSTITUTES   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

thalassemia; Hepatitis C; Iron overload; Pegylated interferon ; Ribavirin

Indexed keywords

DEFEROXAMINE; IRON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ALOPECIA; ANEMIA; ANXIETY; ARTICLE; BACKACHE; BLOOD TRANSFUSION; BODY WEIGHT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOLYSIS; HEPATITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; IRRITABILITY; LIVER BIOPSY; LIVER FUNCTION; LIVER WEIGHT; NAUSEA; NECK PAIN; NEUTROPENIA; PATIENT COMPLIANCE; RASH; SIDE EFFECT; SORE THROAT; THALASSEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; IRON; LIVER; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SAFETY; THALASSEMIA;

EID: 48749083577     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12352     Document Type: Article

References (22)

1. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004;104:34-9.
2. Prati D, Zanella A, Farma E, De Mattei C, Bosoni P, Zappa M, et al. A multicenter prospective study on the risk of acquiring liver disease in antihepatitis C virus negative patients affected from homozygous β-thalassemia. Blood 1998;92:3460-4.
3. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
4. Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36:5(Suppl 1):S226-36.
5. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2005;31:997-1004.
6. Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP, Skaug K, et al. Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75.
7. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in β-thalassemics with chronic hepatitis C. Blood 1997;90:2207-12.
8. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002;117:755-8.
9. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, et al. Hepatic iron overload does not prevent a sustained virological response to interferon-α therapy: a long term follow-up study in hepatitis C-infected patients with β thalassemia major. Am J Gastroenterol 2002;97:982-7.
10. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997;98:850-5.
11. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol 2005;130:644-6.
12. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon α-2a (40 KD)/ribavirin. J Hepatology 2005;43:425-33.
13. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003;121:938-48.
14. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-31.
15. Porter J, Borgna-Pignatti C, Baccarani M, Saviano A, Abish S, Malizia R, et al. Iron chelation efficiency of deferasirox (Exjade, ICL670) in patients with transfusional hemosiderosis. Blood 2005;106:#2690 [Abstract].
16. Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, et al. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006;91:1367-71.
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
19. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon α-2a plus ribavirin. Gastroenterology 2006;131:1040-8.
20. Ouzan D, Khiri H, Penaranda G, Joly H, Halfon P. Kinetics of hepatitis C virus RNA load during pegylated interferon α-2a and ribavirin treatment in naive genotype 1 patients. Compar Hepatol 2005;4:9.
21. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
22. Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, et al. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem 2005;280:9049-57.